<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305938</url>
  </required_header>
  <id_info>
    <org_study_id>KBS004</org_study_id>
    <nct_id>NCT04305938</nct_id>
  </id_info>
  <brief_title>A Human Clinical Study to Collect Calibration and Performance Data for the RBA-1 and KBS-1</brief_title>
  <official_title>A Human Clinical Study to Collect Calibration and Performance Data for the RBA-1 and KBS-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaligia Biosciences, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaligia Biosciences, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Kaligia Biosciences KBS Systems 1.0(b) analyte monitoring device is to&#xD;
      measure the blood analyte levels in patients. The KBS Systems 1.0(b) device avoids the common&#xD;
      practice of accessing the vein to draw blood for conventional laboratory analysis. Instead,&#xD;
      the KBS Systems 1.0(b) device uses Raman Spectroscopy to acheive the measurement of various&#xD;
      blood analytes through the use of only approximately 40Âµl of blood. Such a small volume of&#xD;
      blood can be sampled via a finger prick procedure rather than needing a larger volume of&#xD;
      blood sampled via a venipuncture. The spectra contain information of all the molecules&#xD;
      present in the blood (RBCs, hemoglobin, glucose, sodium, potassium, etc.). From these&#xD;
      spectra, the system is able to analyze the blood and provide results in a matter of minutes,&#xD;
      rather than hours or even, in some cases, days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analyte validation</measure>
    <time_frame>6 months</time_frame>
    <description>CLIA laboratory analyte values will be compared to device analyte readings and inform machine learning of device software learning to achieve device calibration and validation of readings.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Calibration and Validation of Analyte Testing System</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Minimally invasive and non-invasive blood analyte measurement</intervention_name>
    <description>Rapid point-of-care minimally invasive blood analyzer consisting of a spectrometer and a computer loaded with Kaligia software that controls the data acquisition and signal processing to interpret blood analyte measurement.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The research subjects subjected to the test articles used in this study will be hospital&#xD;
        patients with doctor-prescribed blood tests as standard of care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults &gt; 18 yrs of age.&#xD;
&#xD;
          -  Willingness and ability to provide informed consent&#xD;
&#xD;
          -  Hospital patients with a physician-prescribed laboratory blood test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. People with clotting factor disorders and/or currently taking anticoagulation&#xD;
             medication.&#xD;
&#xD;
          2. Has any other medical condition that, in the opinion of the Investigator, would&#xD;
             interfere with the person's participation in this study (i.e. double arm amputee).&#xD;
&#xD;
          3. Any skin abnormalities or tattoos located on the palm(s) of the hand(s). The left palm&#xD;
             is preferred for this study; however, the right palm can be used if the left palm is&#xD;
             excluded.&#xD;
&#xD;
          4. Parkinson's disease, dyskinesia, tremors, or similar that may make it challenging for&#xD;
             said person to hold their hand on the device in a still and stable manner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Janice Shirley, MPH</last_name>
    <phone>813-919-8857</phone>
    <email>advancedclinicalresearch@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fazal Fazlin</last_name>
    <phone>727-234-8877</phone>
    <email>ffazlin@kaligiabiosciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Olvedy</last_name>
      <phone>813-660-6643</phone>
      <email>JOlvedy@tgh.org</email>
    </contact>
    <contact_backup>
      <last_name>TGH Office of Clinical Research</last_name>
      <phone>813-844-2673</phone>
      <email>research@tgh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

